Dr. Stuart E. Pollack Joins Firm’s New York Office

NEW YORK (October 4) – Kilpatrick Townsend & Stockton announced today the addition of Dr. Stuart E. Pollack to the firm’s New York office as a partner on the Patent Litigation Team in its highly recognized Intellectual Property Department. 

Dr. Pollack will be reuniting with Kilpatrick Townsend partners Michael Furrow, April Abele Isaacson, and Brian O’Reilly who joined the firm in October 2020. He worked closely with each of them at his previous firm, DLA Piper. 

“Stuart has the rare combination of incredible technical prowess, encyclopedic knowledge of the law, and fearlessness in court,” said Michael. “I am thrilled to be working with – and learning from – him again.”

“Clients are quickly put at ease by Stuart’s ability to understand and craft legal strategy to align with business objectives,” added April. “And he’s a joy to work with.”

“Stuart’s depth of trial experience in biopharma patent litigation places him in the top stratum in our field,” stated Brian. “Our clients greatly value, and will benefit tremendously, from that knowledge.”

Dr. Pollack focuses his practice on high-stakes patent disputes. He has helped innovator clients obtain favorable judgments in several suits on behalf of pioneer drug companies under the Hatch-Waxman Act. His experience includes 16 bench and jury trials in federal district court, nine appeals at the Federal Circuit, and numerous cases before the International Trade Commission and Patent Trials and Appeals Board. Dr. Pollack’s extensive litigation work has also included biotechnology inventions and biological drugs, industrial chemicals, food additives, medical devices, polymers, optics, chemical reactors, and various mechanical inventions.

Dr. Pollack is also routinely sought out for his strategic patent counseling and opinion work. He enjoys assisting clients to arrive at optimal patent positioning for their most commercially important products.

“Stuart will add valuable experience and depth to our growing biopharma and chemical patent litigation practice,” said Kilpatrick Townsend Patent Litigation Team Co-Chairs Steve Moore and Matias Ferrario. “We were immediately impressed with his strong track record on behalf of branded biologics and drug companies. And Stuart’s collaborative spirit combined with his familiarity and strong relationship with a number of partners in the firm, made his addition to the team a natural fit and a home run for clients.”  

Dr. Pollack’s hire follows the recent additions earlier this year of patent litigation partners Bob Hollingshead in Tokyo and Washington D.C., Aarti Shah in Washington, D.C., Wes Overson in San Francisco, and in late 2020, patent litigation counsel Abby Markeson in Seattle. 

“I am very familiar with the high level of talent among the Kilpatrick Townsend patent litigators, and have seen firsthand how much biopharma clients value that talent,” said Stuart. “It has been a pleasure following the numerous successes that Mike, April, and Brian have been able to provide clients since moving to Kilpatrick Townsend, and I look forward to bringing my industry expertise and legal experience to the table. It is an honor to be a part of a firm with an elite patent bench and an international reputation for excellence across intellectual property.”

Dr. Pollack has been recognized by numerous industry-leading directories and rankings, including: a "Life Sciences Star" by The Legal Media Group, noting him as one of a few preeminent Life Science practitioners in the United States; The Legal 500 United States; IAM Patent 1000; a New York Metro Super Lawyer; and a national "Star" in the area of Intellectual Property by the Euromoney / Institutional Investor's Benchmark: America's Leading Litigation Firms and Attorneys. 

Dr. Pollack received his J.D. from the Columbia University School of Law where he was a Kent Scholar; his Ph.D. in Physical Chemistry from Northwestern University; his M.S. in Chemistry from Northwestern University; and his B.A. in Chemistry from the University of Rochester. He has published more than a dozen peer-reviewed papers involving nanotechnology for scholarly journals such as those published by the American Physical Society, and has published numerous articles in legal journals regarding patent law, making him a thought leader in pharmaceutical patent law. 

***